This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Galectin Therapeutics Names Industry-Veteran Jack W. Callicutt Chief Financial Officer

Stocks in this article: GALT

NORCROSS, Ga., June 21, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced the appointment of Jack W. Callicutt to the position of Chief Financial Officer, effective July 1, 2013.

Mr. Callicutt will lead the Company's financial activities, including financial reporting, accounting, risk management, public company governance, interaction with capital markets, and public and investor relations. As a member of the senior management team, Mr. Callicutt will play a key role in shaping corporate strategy as we advance key product assets in the clinic.  He will also help assure that the company has the financial resources to realize its vision for its pipeline of clinical development assets which is critical to create shareholder value.

"Jack's demonstrated leadership and deal-making capabilities coupled with his financial management experience and industry knowledge makes him an ideal fit with the needs of the company and further consolidates our leadership group in the Atlanta office. I am looking forward to working closely with Jack and am excited to add an individual of Jack's caliber to our management team," said Dr. Peter G. Traber, Chief Executive Officer and Chief Medical Officer of Galectin Therapeutics Inc. "I also wish to sincerely thank Mr. Thomas McGauley for his years of service to the company, including the last 14 months as acting CFO, and for agreeing to work closely with Jack to assure an orderly transition."

Mr. Callicutt has over 22 years of public and private company experience including more than a decade of audit, tax, and SEC registrant experience with a major accounting firm. He was most recently CFO for REACH Health, Inc., a telemedicine firm, where he completed a $4 MM private placement. Previous positions include CFO of Vystar Corporation, a public medical device company whose latex products are devoid of antigenic proteins, where he led all areas of financial reporting, accounting, treasury, risk management and administration and secured over $4.5 MM in financing. Previous experiences also include CFO roles at private companies including IVOX and Tikvah Therapeutics, and at Coratus Genetics, a publicly traded biopharmaceutical company. His broad background of experiences spanning a variety of technology intensive industries underpinned by a decade-long senior level role at Deloitte, positions him well to meaningfully contribute to the advancement of the company.

Jack is a Certified Public Account and graduated cum laude with a BBA degree in Accounting and Computer science from Delta State University. Jack is active in community affairs such as the Atlanta Community Food Bank, Habitat for Humanity, and resides with his family in Alpharetta, Georgia.  

About Galectin TherapeuticsGalectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com. Follow us on Twitter @GalectinGALT

SOURCE Galectin Therapeutics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs